A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes
- Conditions
- Diabetes Mellitus, Type 1
- Registration Number
- NCT01771250
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
This study has two parts. Each participant will receive a daily injection of insulin peglispro during one treatment period and a daily injection of insulin glargine during the other treatment period. Each treatment period is 3 to 4 weeks and is followed by procedures to look at how the body uses or stores fats while taking each study drug.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
- Type 1 diabetic for more than 1 year with glycated hemoglobin (HbA1c) of less than 8.5%
- Otherwise fit and healthy
- Non smoker
- Taking medication or supplements other than insulin to control diabetes.
- Suffered a hypoglycemic event in the last 12 months that required hospitalization or have poor awareness of hypoglycemia
- Taking fibrates, thyroid replacement therapy, testosterone, beta blockers or systemic corticosteroids
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentrations Day 22: 240 minutes (min) to 420 min VLDL-TG average total concentration calculated at steady state from 240 to 420 minutes during dosing with insulin peglispro and insulin glargine.
VLDL-TG Secretion Rate Day 22: 240 min to 420 min VLDL-TG secretion rates are calculated at steady state during dosing with insulin peglispro and insulin glargine.
VLDL-TG Oxidation Rate Day 22: 240 min to 420 min VLDL-TG oxidation rates are calculated at steady state during dosing with insulin peglispro and insulin glargine.
VLDL-TG Clearance Rate Day 22: 240 min to 420 min VLDL-TG clearance rates are calculated at steady state during dosing with insulin peglispro and insulin glargine.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇩🇰Aarhus, Denmark
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.🇩🇰Aarhus, Denmark